Editor’s Note: Welcome to “Eye Catching: Let's Chat,” a blog series featuring contributions from members of the ophthalmic community. These blogs are an opportunity for ophthalmic bloggers to engage with readers with about a topic that is top of mind, whether it is practice management, experiences with patients, the industry, medicine in general, or healthcare reform. The series continues with this blog by Neel R. Desai, MD. The views expressed in these blogs are those of their respective contributors and do not represent the views of Ophthalmology Times or UBM Medica.
Preoperative treatment of ocular surface disease (OSD) is an asset that many cataract surgeons tend to undervalue. I often talk to peers who treat OSD as a nuisance problem that gets in the way of them proceeding with the ultimate goal of cataract surgery, but for those of us who are outcomes-driven and see that those outcomes help build the reputation and good will we need to grow our practices, treating OSD prior to surgery is an important goal in itself, not a speed bump on the road to surgery.
Look at These Numbers
If you think treating OSD before surgery is a burden, consider these numbers:
As these studies help illustrate, by treating OSD, our practices accumulate better outcomes and happier patients, reduce costly postoperative chair time and enhancements, and get reimbursed for OSD treatment. It’s a win for patients, physicians, and our businesses.
Pre-Op Care for Mild, Moderate or Severe OSD
The first step in this process is to get patients to understand the importance of treating OSD before surgery. I tell my patients, “I’d rather do this the right way than the fast way. If a surgeon were to neglect treating this and rush you to cataract surgery, you would have less-than-ideal results and not be as happy as you should be. We want to do this right the first time.” Based on the severity of OSD – mild, moderate or severe – I follow a protocol to get the best achievable outcome.
I follow the same treatments as mild and moderate OSD, while adding other appropriate therapies. For example, I may combine treatments, following thermal pulsation therapy with IPL. For some patients, I combine superficial keratectomy with PROKERA. Not only is the intensity of treatment higher for severe OSD, but it also requires more time for therapies to produce optimal results. Hence, it is important to impress upon patients the value-added benefit of this optimization process in terms of better, more accurate outcomes and greater breadth of choice in lens implant opportunities.
Outcomes and post-op care
Postoperative care for OSD begins before surgery, when we teach patients that the problem is chronic and requires long-term treatment. My patients have a long-term plan before surgery, which usually involves continuing traditional at-home therapies and prescription medications. If they have had thermal pulsation therapy and/or IPL, they will return for follow-up sessions, which usually taper to once per year. Patients understand that we have optimized their ocular surface, delivered the surgical outcomes they desired, and now we need to keep their ocular surface healthy and clear.
In our practice, we have seen that optimizing the ocular surface elevates patient satisfaction and word-of-mouth referrals. It also boosts our rates of refractive cataract surgery. Before treating OSD, we would offer refractive surgery to about 50% of cataract patients, but after treatment, that number rises to about 90%. Patients get better outcomes not only thanks to more accurate biometry, but also because they have expanded access to high-technology lenses and procedures. When our patients have better vision and our practice is growing, we cannot look at treating OSD as a nuisance – it is most definitely an opportunity.
Neel R. Desai, MD, is director of Cornea, Cataract, and Refractive Services at The Eye Institute of West Florida; medical director, Lions Eye Institute for Transplant Research; and president and CEO, Clarity Visionary Consulting. He is a consultant to Allergan, BioTissue, Lumenis, Johnson & Johnson Vision, and Shire.
1. Trattler WB, Majmudar PA, Donnenfeld ED, McDonald MB, Stonecipher KG, Goldberg DF. The Prospective Health Assessment of Cataract Patients' Ocular Surface (PHACO) study: the effect of dry eye. Clin Ophthalmol. 2017;7(11):1423-1430.